Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 3
2014 3
2015 3
2016 2
2017 2
2018 2
2019 3
2020 1
2021 1
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
The eukaryotic translation initiation factor eIF4E reprograms alternative splicing.
Ghram M, Morris G, Culjkovic-Kraljacic B, Mars JC, Gendron P, Skrabanek L, Revuelta MV, Cerchietti L, Guzman ML, Borden KLB. Ghram M, et al. Among authors: culjkovic kraljacic b. EMBO J. 2023 Apr 3;42(7):e110496. doi: 10.15252/embj.2021110496. Epub 2023 Feb 27. EMBO J. 2023. PMID: 36843541 Free PMC article.
eIF4E3, a new actor in mRNA metabolism and tumor suppression.
Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden KL. Volpon L, et al. Among authors: culjkovic kraljacic b. Cell Cycle. 2013 Apr 15;12(8):1159-60. doi: 10.4161/cc.24566. Epub 2013 Apr 9. Cell Cycle. 2013. PMID: 23587918 Free PMC article. No abstract available.
Aiding and abetting cancer: mRNA export and the nuclear pore.
Culjkovic-Kraljacic B, Borden KL. Culjkovic-Kraljacic B, et al. Trends Cell Biol. 2013 Jul;23(7):328-35. doi: 10.1016/j.tcb.2013.03.004. Epub 2013 Apr 10. Trends Cell Biol. 2013. PMID: 23582887 Free PMC article. Review.
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J, Furman RR, Chen Z, Shore TB, Phillips AA, Mayer S, Hsu J, van Besien K, Leonard JP, Borden KLB, Inghirami G, Martin P, Cerchietti L. Marullo R, et al. Among authors: culjkovic kraljacic b. Cancer Res. 2024 Jan 2;84(1):101-117. doi: 10.1158/0008-5472.CAN-23-1992. Cancer Res. 2024. PMID: 37801604 Free PMC article.
Inducible drug modification: a new form of resistance.
Culjkovic-Kraljacic B, Zahreddine HA, Borden KL. Culjkovic-Kraljacic B, et al. Cell Cycle. 2014;13(16):2485-6. doi: 10.4161/15384101.2014.946372. Cell Cycle. 2014. PMID: 25486186 Free PMC article. No abstract available.
Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, Zakaria C, Szlachtycz D, Yee K, Borden KLB. Assouline S, et al. Among authors: culjkovic kraljacic b. Haematologica. 2023 Nov 1;108(11):2946-2958. doi: 10.3324/haematol.2023.282791. Haematologica. 2023. PMID: 36951168 Free PMC article. Clinical Trial.
26 results